Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome

NCT ID: NCT06045351

Last Updated: 2025-02-18

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 142 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-01
• Study Completion Date: 2026-12-31

Brief Summary

Poly cystic Ovarian Syndrome (PCOS) is an endocrine disorder of reproductive age defined by "the presence of any two out of three criteria: oligo and/or anovulation, excess androgen activity and/or polycystic ovarian morphology on ultrasound". Considering role of vitamin D (VD) (3, 4) and high prevalence (58%) of deficiency in PCOS of Pakistan. Researchers hypothesized that its correction would improve response to standard PCOS treatment. The objective is to compare PCOS parameters in intervention group (Group A) receiving VD supplementation and then PCOS care with control group (Group B) receiving standard PCOS care and then VD supplementation. A randomized open label trial: delayed-start design will be conducted on VD deficient PCOS females VD < 20ng/ml ; Group A will receive VD injections 600,000 I.U I/M once with 1 gram calcium supplement daily in the initial 12 weeks. After that standard PCOS care; i) Glucophage XR 750 mg (once for 15 days then twice daily) ii) progesterone supplementation (1 capsule Progeffik 100 mg every 3 weeks, then 1 week off) and iii) calcium supplements will be given for next 12 weeks. PCOS females in Group B will receive standard PCOS care (same) with addition of VD and calcium supplementation after 12 weeks till study end point. Study outcomes will be comparison of i) hyperandrogenism by Free Androgen Index [Total Testosterone, Steroid Hormone Binding Globulin ii) insulin Resistance by HOMA-IR (serum Insulin, Fasting Blood Glucose) and iii) oxidative stress by Total Antioxidant Capacity after 24-weeks in these Groups'd levels after supplementation will be assessed for confirmation of correction and calcium and albumin levels for detection of hypercalcemia. Results of this study will inform the clinicians to add VD before or after the standard PCOS care for rectification of endocrine and metabolic derangements as a cost-effective treatment and prevention strategy in these females.

Detailed Description

This study will comprise of two groups (A and B) with 71 participants in each group carried for a duration of 24 weeks.

Intervention Details for Group A (Duration 1-12 weeks):

Participants will be given Vitamin D (VD) supplementation at a dose of 600,000 IU along with Calcium 1000 mg/day.

Mid-Point (At 12 weeks):

Patients will have a consultation for clinical interpretation. They will undergo biochemical assessment, including the estimation of Insulin Resistance, Free Androgen Index, and Total Antioxidant Capacity.

After 12 weeks They will receive standard treatment for Polycystic Ovary Syndrome (PCOS), which includes Glucophage XR 750 mg once at dinner for 15 days, then twice daily. Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off and Calcium 1000 mg/day

Intervention Details for Group B (Duration 1-12 weeks):

Participants in Group B will receive standard PCOS treatment mentioned earlier:

Glucophage XR 750 mg once at dinner for 15 days, then twice daily. Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off. Additionally, they receive Calcium 1000 mg/day.

Mid-Point (At 12 weeks):

Patients will have a consultation for clinical interpretation. They will undergo biochemical assessment, including the estimation of Insulin Resistance, Free Androgen Index, and Total Antioxidant Capacity.

Intervention Details for Group A (After 12 weeks)

They will receive VD supplementation (600,000 IU) during this time and continue to receive Calcium 1000 mg/day.

Calculations of HOMA-IR and Free Androgen Index will be done at 12 and 24 weeks and the results will be compared.

{HOMA-IR: HOMA- IR index, a commonly used marker of IR, will be calculated using the formula: HOMA-IR = fasting glucose levels [mmol/L] × fasting insulin levels [μU/mL]/22.5 Free Androgen Index will be derived from TT and SHBG, normally measured in nanomoles per liter. FAI =100 (TT /SHBG)}

Conditions

Anovulatory Infertility

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

VD supplementation

Experimental Group (Group A; n=71):

The intervention (experimental) group will receive VD injections 600,000 I.U I/M once with 1 gram calcium supplemental daily in the initial 12 weeks. After that standard PCOS care; i) Glucophage XR 750 mg (once for 15 days then twice daily) ii) progesterone supplementation (1 capsule Progeffik 100 mg every 3 weeks, then 1 week off) and iii) calcium supplements will be given for next 12 weeks.

Group Type: EXPERIMENTAL

Vitamin D

Intervention Type: DRUG

Intervention Group Initial 12 weeks;

• VD supplementation (600,000 IU I/M) once during the study period
• Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;
• Glucophage XR 750 mg once at dinner for 15 days then twice daily
• Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off
• Calcium 1000 mg/day

Control

Control Group (Group B; n=71):

Participants will receive standard PCOS treatment; Glucophage XR 750 mg once at dinner for 15 days then twice daily and Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off for initial-- 12 weeks.

Then VD supplementation (600,000 IUI/M) will be given once during the study period with Calcium 1000 mg/day and continued Standard PCOS treatment from 12- 24 weeks

Group Type: ACTIVE_COMPARATOR

Active Comparator

Intervention Type: OTHER

Active Comparator (Group B; n=71):

Initial-- 12 weeks;

• Standard PCOS;
• Glucophage XR 750 mg once at dinner for 15 days then twice daily
• Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks
• VD supplementation (600,000 IUI/M) once during the study period
• Calcium 1000 mg/day
• Standard PCOS Continued

Interventions

Vitamin D

Intervention Group Initial 12 weeks;

• VD supplementation (600,000 IU I/M) once during the study period
• Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;
• Glucophage XR 750 mg once at dinner for 15 days then twice daily
• Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off
• Calcium 1000 mg/day

Intervention Type: DRUG

Active Comparator

Active Comparator (Group B; n=71):

Initial-- 12 weeks;

• Standard PCOS;
• Glucophage XR 750 mg once at dinner for 15 days then twice daily
• Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks
• VD supplementation (600,000 IUI/M) once during the study period
• Calcium 1000 mg/day
• Standard PCOS Continued

Intervention Type: OTHER

Other Intervention Names

Experimental; Group A; Group B

Eligibility Criteria

Inclusion Criteria

• Recently diagnosed PCOS with presence of at least 2 of these 3 elements: clinical or biochemical signs of hyperandrogenism, chronic anovulation and polycystic ovaries (1) (from reports of available routine TVS), with VDD serum levels VD <20 ng/ml(10), age range 18- 45 years, from all ethnic background will be included.

Exclusion Criteria

• : Exclusion of subjects will be done by the Co-Principal Investigators (Co-PI) after history, examination and complete evaluation in the respective clinics. All female subjects meeting any of the following criteria will be excluded from the study

• Pregnancy
• Hypercalcemia (plasma calcium concentrations> 2.65 mmol/L)
• Tuberculosis or other granulomatous disorders
• Chronic liver disease or alanine transaminase (ALT) level 3 times higher than the normal limit, chronic
• Kidney disease or serum creatinine >2.0 mg/dL,
• Drug Therapies: VD replacement ; participants who had received VD injection in the last 3 months prior to recruitment in the study, oral contraceptives, hormonal replacement therapy, glucocorticoids, calcium supplementation, insulin-sensitizing drugs (incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers, immunosuppressant, chemotherapeutic agents, antimicrobials (Rifampicin, Isoniazid, Hydroxychloroquine) or any other drug modifying lipid metabolism in the previous 3 months prior to study
• Suffering from congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, type 2 Diabetes Mellitus, renal, hepatic or thyroid disorders, hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease, Hepatic failure, cystic fibrosis, vaginal bleeding of unknown etiology or /and suffering from COVID-19 (within 3 months).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Pakistan Science Foundation

OTHER

Sponsor Role: collaborator

Aga Khan University

OTHER

Sponsor Role: lead

Responsible Party

Rehana Rehman

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Rehana Rehman, PhD

Role: PRINCIPAL_INVESTIGATOR

Aga Khan University

Locations

Aga Khan University Hospital

Karachi, Sindh, Pakistan

Site Status: RECRUITING

Countries

Pakistan

Central Contacts

Rehana Rehman, PhD

Role: CONTACT

drrehana7@gmail.com

00922134864460 ext. 4460

Facility Contacts

Rehana Rehman, PhD

Role: primary

rehana.rehman@aku.edu

03072227775

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

AKUBBS

Identifier Type: -

Identifier Source: org_study_id